Small molecule-based therapy for p53-deficient tumors: Sirtuin2 suppresses & increases the expression of DNp63α & IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 6/May/2015, 11.41 am

Regenerative therapy for Diabetes mellitus: Follicule stimulating hormone (FSH) increases human pancreatic beta cell replication via down regulation of its target gene DYRK1A, 6/May/2015, 11.26 am
May 6, 2015
Interleukin-based neuropathic pain relieving therapy: Interleukin-1β (IL-1β) inhibits neuropathic pain via down regulation of T cell–derived leukocyte elastase, 6/May/2015, 12.11 am
May 6, 2015
Show all

A recent study from the Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January  2015 issue of the Journal “Nature” (the no.1 journal in Science; and I.F:42) by Prof. Flores ER, Venkatanarayan A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Small molecule-based therapy for p53-deficient tumors: Sirtuin2 suppresses &  increases the expression of DNp63α &  IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene.

Significance:  Cancer suppressor p53 is mutated in more than 50% of cancers of different origin, while its pathway is altered in about 80% of tumors. This study suggests a therapeutic strategy as to how p53-deficient or mutant p53 expressing human cancers can be cured by suppressing its “oncogenic version of homologous protein p63” such as DNp63α. 

It has been shown that Sirtuin2 functions as a tumor suppressor in skin.  This study suggests that, Sirtuin2, by suppressing the expression of its target gene, it may decrease the expression of DNp63α; and thereby increase the expression of IAPP (Amylin). Thus, pharmacological formulations encompassing “Sirtuin2 activators”  can be used to inhibit the progression of p53-deficient human tumors, including melanoma.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

CitationBoominathan, Small molecule-based therapy for p53-deficient tumors: Sirtuin2 suppresses &  increases the expression of DNp63α &  IAPP (Amylin), respectively, and induces regression of p53-mutated human tumors via down regulation of its target gene, 6/May/2015, 11.41 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How Sirtuin2 suppresses the expression of DNp63α and increases the expression of IAPP

* Research cooperation

Comments are closed.